Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Eql Pharma AB is a pharmaceutical company specializing in the development, licensing, and distribution of generic medicines. The primary purpose of Eql Pharma is to enhance accessibility to affordable healthcare through high-quality generic pharmaceuticals. The company focuses on niche areas within the pharmaceutical sector, targeting specific therapeutic segments where competition is minimal and demand is unmet. Eql Pharma operates across several geographical markets, predominantly in the Nordic region, aiming to fulfill the needs of hospitals, pharmacies, and healthcare providers. Its portfolio includes a diverse range of drugs in various therapeutic categories, supported by extensive research and a commitment to regulatory compliance. Eql Pharma plays a vital role in the healthcare market by ensuring the availability of cost-effective drug alternatives, thereby contributing to the optimization of health spending while maintaining treatment efficacy. As a player in the ever-evolving pharmaceutical landscape, Eql Pharma continues to adapt and expand, driven by innovation and a strategic focus on niche markets.
kr 2.19
kr 0.06 (-2.45%)
EOD Jun 23, 2026 · Twelve Data
11.25% operating margin is respectable but not wide. ROIC at 4.69%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 15.8%, still solid. Margins contracted 6.5pp, which offsets some of the top-line progress.
ROIC dropped from 10.80% to 4.69%, capital efficiency is deteriorating. Negative free cash flow of -kr 39M. The business is consuming cash, not generating it.
5.1x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 433M
▲ +15.8% YoY
Net Income (TTM)
kr 13M
▼ -70.9% YoY
Op. Margin
11.25%
▼ -6.5pp YoY
ROIC
4.69%
▼ -6.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 39M
▲ +85.6% YoY
Op. Cash Flow (TTM)
kr 36M
▲ +248.0% YoY
Net Debt
kr 398M
Cash & Equiv.
kr 87M
3Y CAGR: +18.5%
Continue Research
At a P/E of 5.1, Eql Pharma AB (EQL.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Eql Pharma AB scores 33/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Eql Pharma AB scores 33 out of 100 on Intrinsiqq's quality score, passing 2 of 7 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a 11.3% operating margin and a 4.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh EQL.XSTO's valuation and scores 33/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.